Acquisitions - Additional Information 1 (Details) - USD ($) $ in Thousands |
3 Months Ended | 9 Months Ended | ||
|---|---|---|---|---|
Sep. 30, 2026 |
Sep. 30, 2025 |
Sep. 30, 2026 |
Sep. 30, 2025 |
|
| Business Combination [Line Items] | ||||
| Change in the estimated fair value of contingent consideration | $ (28,361) | $ 6,173 | ||
| Cobalt Biomedicine, Inc | Acquisition Agreement | Location, Statement of Income, Balance [Axis]: us-gaap:ResearchAndDevelopmentExpense | ||||
| Business Combination [Line Items] | ||||
| Change in estimated fair value of success payment | $ 7,600 | $ (4,800) | 2,300 | (8,500) |
| Change in the estimated fair value of contingent consideration | $ 55,500 | $ 2,000 | $ 28,400 | $ (6,200) |
| X | ||||||||||
- Definition Gain expense in connection with change in estimated fair value of success payment liabilities. No definition available.
|
| X | ||||||||||
- Definition Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table. Reference 1: http://www.xbrl.org/2003/role/exampleRef
|
| X | ||||||||||
- Definition Amount of increase (decrease) in value of liability in contingent consideration arrangement in business combination, including, but not limited to, difference arising upon settlement. Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef
|
| X | ||||||||||
- Details
|
| X | ||||||||||
- Details
|
| X | ||||||||||
- Details
|